Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trialsMult. Scler. 2022 Sep 01;28(10)1606-1619, EM Strijbis, P Repovic, J Mostert, JD Bowen, BM Uitdehaag, G Cutter, MW Koch
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.